SCHEMBL29520333

SCHEMBL29520333

CC(=O)Oc1ccc(COP(=O)(CC(CCC(=O)Cc2ccc(OC(C)=O)cc2)C(=O)O)OCc2ccc(OC(C)=O)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.47
GAA P10253 2/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
ELANE P08246 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HSP90AA1 P07900 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.33
PRSS1 P07477 1/20 0.33
TMPRSS15 P98073 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17533511 0.90 FOLH1 (0.59) FOLH1PRSS1TMPRSS15
SCHEMBL17533512 0.87 FOLH1 (0.47) FOLH1GAANPC1RAB9ASMN1; SMN2
SCHEMBL19220639 0.86 FOLH1 (0.55) FOLH1PRSS1TMPRSS15
SCHEMBL29520612 0.84 FOLH1 (0.47) FOLH1GAANPC1RAB9ASMN1; SMN2
SCHEMBL19220644 0.83 FOLH1 (0.44) FOLH1GAAPOLBKMT2AALDH1A1
SCHEMBL17533510 0.81 FOLH1 (0.48) FOLH1NPC1RAB9ASMN1; SMN2ELANE
SCHEMBL21919736 0.81 FOLH1 (0.43) FOLH1GAAPOLBKMT2AALDH1A1
SCHEMBL19220650 0.78 FOLH1 (0.45) FOLH1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL21919745 0.75 FOLH1 (0.46) FOLH1POLBKMT2A
SCHEMBL17533764 0.74 SMN1; SMN2 (0.36) FOLH1NPC1RAB9ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932664-B2 Prodrugs of prostate specific membrane antigen (PSMA) inhibitor THE JOHNS HOPKINS UNIVERSTY (US) 2024-03-19 US disclosed
US-20230115651-A1 PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2023-04-13 US disclosed
US-11325931-B2 Prodrugs of prostate specific membrane antigen (PSMA) inhibitor THE JOHNS HOPKINS UNIVERSITY (US) 2022-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325931-B2 Prodrugs of prostate specific membrane antigen (PSMA) inhibitor FOLH1, KLK3, DNPEP FOLH1 1/4885GAA 328/4885NPC1 847/4885
US-20230115651-A1 PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR FOLH1, KLK3, DNPEP FOLH1 1/4885GAA 241/4885NPC1 727/4885
US-11932664-B2 Prodrugs of prostate specific membrane antigen (PSMA) inhibitor FOLH1, KLK3, DNPEP FOLH1 1/4885GAA 328/4885NPC1 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.